Mallinckrodt and Endo Announce $6.7 Billion Merger to Create Diversified Pharmaceutical Leader
Mallinckrodt and Endo have agreed to merge in a $6.7 billion cash and stock deal123.
The combined company is expected to generate approximately $3.6 billion in revenue in 202512.
Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive 49.9% ownership plus $80 million in cash134.
Siggi Olafsson, current Mallinckrodt CEO, will become CEO of the combined company, while Paul Efron from Endo's board will serve as chairman12.
The merger aims to create a larger, more diversified entity with presence in branded and generic drugs across various therapeutic areas4.
Both companies have recently emerged from bankruptcy proceedings related to opioid litigation123.
The combined company plans to separate its generics and sterile injectables businesses at a later date24.
The merger is expected to generate at least $150 million in annual cost savings by the third year4.
The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals24.
The combined company will be headquartered in Dublin, Ireland, with its U.S. headquarters to be determined later24.
Sources:
1. https://www.pharmaceutical-technology.com/news/mallinckrodt-and-endo-sign-6-7bn-merger-deal/
2. https://medcitynews.com/2025/03/mallinckrodt-endo-merger-acquisition-ndoi/
3. https://www.biospace.com/business/troubled-drugmakers-mallinckrodt-endo-officially-announce-6-7b-merger
4. https://www.genengnews.com/topics/drug-discovery/mallinckrodt-endo-plan-6-7b-merger/